A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug ...

A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug Administration.

Alzheimer’s Association urging ‘action now’ for awareness month June is Alzheimer’s and Brain Awareness Month, and the Alzheimer’s Association is urging patients, caregivers, and supporters to “take ...

The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease. “The approval of once every four-week ...

Axsome Therapeutics plans this year to ask the U.S. Food and Drug Administration (FDA) to approve its oral therapy AXS-05 as a treatment for agitation related to Alzheimer’s disease.

Muna Therapeutics and GSK said they will collaborate to identify and validate new therapeutic targets for Alzheimer’s disease, a step that could pave the way for new treatments for the condition.

Foralumab, an investigational nasal spray being developed by Tiziana Life Sciences, has been cleared by the U.S. Food and Drug Administration (FDA) for expanded use to treat moderate Alzheimer’s ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Elecsys Phospho-Tau 217 (pTau217), a blood-based biomarker test that can help distinguish Alzheimer’s disease ...

Anavex is preparing meetings with regulatory authorities in the U.S., Europe, and Asia-Pacific to discuss Anavex 2-73’s potential approval.

Among people with a genetic form of Alzheimer's disease, those with more formal education tend to be older at disease onset, a study says.

The PrecivityAD blood test was found to influence doctors' decisions to treat for Alzheimer's disease in a real-world study.

"Encouraging results" were reported in eight Alzheimer’s patients with dementia who were treated with the experimental therapy COYA 301.